Summit Therapeutics Inc.
SMMT
$16.18
$0.060.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -24.71% | -71.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.96% | -58.80% | |||
| Operating Income | 3.96% | 58.80% | |||
| Income Before Tax | 5.44% | 59.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.44% | 59.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.44% | 59.03% | |||
| EBIT | 3.96% | 58.80% | |||
| EBITDA | 3.97% | 58.80% | |||
| EPS Basic | 8.31% | 59.07% | |||
| Normalized Basic EPS | 8.31% | 59.06% | |||
| EPS Diluted | 8.31% | 59.07% | |||
| Normalized Diluted EPS | 8.31% | 59.06% | |||
| Average Basic Shares Outstanding | 3.12% | 0.11% | |||
| Average Diluted Shares Outstanding | 3.12% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||